Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Lianchun Xiao"'
Autor:
Shehab F. Mohamed, Hagop M. Kantarjian, Guillermo Garcia-Manero, Rita Assi, Courtney D. DiNardo, Nicholas J. Short, Lucia Masarova, Elias Jabbour, Farhad Ravandi, Musa Yilmaz, Jing Ning, Ghayas C. Issa, Abhishek Maiti, Prithviraj Bose, Naval Daver, Lianchun Xiao, Nitin Jain, Marina Konopleva, Naveen Pemmaraju, Tapan M. Kadia
Publikováno v:
Blood. 138:1213-1213
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome characterized by sustained immune overactivation and dysregulation. Malignancy-associated HLH (M-HLH) is associated with particularly dismal outcomes, likely perpetua
Autor:
Paromita Mukherjee, Marina Konopleva, Hagop M. Kantarjian, Naval Daver, Jorge E. Cortes, Lianchun Xiao, Naveen Pemmaraju, Gautam Borthakur, Maro Ohanian, Tapan M. Kadia, Elias Jabbour, William G. Wierda, Nitin Jain, Mark Brandt, Guillermo Garcia-Manero, Farhad Ravandi, Courtney D. DiNardo
Publikováno v:
Blood. 130:892-892
Background: CPX-351 is a liposomal formulation of 5:1 molar combination of cytarabine and daunorubicin (Leukemia research 2010; 34: 1214). Subset analysis in a Phase II study reported improved outcomes in first relapse AML pts with European Prognosti
Autor:
Gary L. Rosner, Tapan M. Kadia, Lianchun Xiao, Sherry Pierce, Susan O'Brien, Elias Jabbour, Deborah A. Thomas, Guillermo Garcia-Manero, Hui Yang, Koyu Hoshino, Carlos E. Bueso-Ramos, Hagop M. Kantarjian
Publikováno v:
Blood. 113:1892-1898
Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL). We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse progno
Autor:
Patricia Kropf, Hagop M. Kantarjian, Henry C. Fung, Philip A. Pancari, Xuelin Huang, Raji Shameem, Woonbok Chung, Jean Pierre J. Issa, Lianchun Xiao
Publikováno v:
Blood. 128:3170-3170
Introduction: DAC is a hypomethylating agent FDA approved for the treatment of advanced myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).Despite its clinical activity, the duration of response is limited and prognosis at rel
Autor:
Kari G. Rabe, Susan Lerner, George A. Calin, Laura Z. Rassenti, William G. Wierda, Zeev Estrov, Alessandra Ferrajoli, M. James You, Neil E. Kay, Steliana Calin, Masayoshi Shimizu, Cristina Ivan, James M. Reuben, Jianhua Hu, Thomas J. Kipps, Nazila Nouraee, Tait D. Shanafelt, Lianchun Xiao, Mariko Ikuo, Michael J. Keating, Susan O'Brien, John T. Manning, Asish K. Ghosh
Publikováno v:
Blood. 122(11)
Noncoding RNAs play a pivotal role in the pathogenesis of chronic lymphocytic leukemia (CLL). We hypothesized that microRNAs (miRs) are involved in the transition from monoclonal B-cell lymphocytosis (MBL) to CLL and tested miR-15a/16-1 cluster, miR-
Autor:
Patricia Kropf, Huang Xuelin, Henry C. Fung, Philip A. Pancari, Hagop M. Kantarjian, Lianchun Xiao, Jean Pierre J. Issa
Publikováno v:
Blood. 126:3775-3775
Background: Epigenetic therapy is the mainstay of treatment for patients with advanced myelodysplastic syndromes (MDS) and for patients with acute myeloid leukemia (AML) who are not candidates for intense chemotherapy. Decitabine (DAC) is an FDA appr
Autor:
Paola Secchiero, Federica Dimitri, Muller Fabbri, Susan Lerner, Milena S. Nicoloso, George A. Calin, William G. Wierda, Stefano Volinia, Giorgio Zauli, Thomas J. Kipps, Massimo Negrini, Simona Rossi, Jianhua Hu, Laura Z. Rassenti, Deepa Sampath, William Plunkett, Lynn L. Barron, Masayoshi Shimizu, Lianchun Xiao, Kevin R. Coombes, Lynne V. Abruzzo, Michael J. Keating, Elisa Barbarotto, Li Jiang
Publikováno v:
Blood. 116(6)
Aberrant expression of microRNAs (miRNAs) has been associated with clinical outcome in patients with chronic lymphocytic leukemia (CLL). To identify a powerful and easily assessable miRNA bio-marker of prognosis and survival, we performed quantitativ
Autor:
Elihu H. Estey, Zeev Estrov, Jean Pierre J. Issa, Jackie Fiorentino, William G. Wierda, Charles Koller, Srdan Verstovsek, Lianchun Xiao, Michael Rytting, Guillermo Garcia-Manero, Susan O'Brien, Gary L. Rosner, Blanca Sanchez-Gonzalez, Hagop M. Kantarjian, Elias J. Jabbour, Jorge E. Cortes, H. Yang, Carlos E. Bueso-Ramos, Stefan Faderl, Farhad Ravandi
Publikováno v:
Blood. 108(10)
We conducted a phase 1/2 study of the combination of 5-aza-2′-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients. A group of 54 patients were t
Autor:
Marina Konopleva, Nitin Jain, Linda J. Bendall, Hagop M. Kantarjian, Rebecca Garris, Jorge E. Cortes, Jordan Basnett, Susan O'Brien, Lianchun Xiao, Naval Daver, Farhad Ravandi, Michael Rytting, Deborah A. Thomas, Xuelin Haung, Kirk Culotta Pharmd, Hongbo Hu, Jitesh D. Kawedia, Mary Ann Richie
Publikováno v:
Blood. 122:3916-3916
Introduction The outcomes of patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) remain poor. Dysregulation of the PI3K/AKT/mTOR signal transduction pathway is central to leukemic cell growth and survival. Everolimus is an oral
Autor:
Elias Jabbour, Guillermo Garcia-Manero, Lianchun Xiao, Al Ali Najla, Asmita Mishra, Eric Padron, Jeffrey E Lancet, Jeffery Bryan, Hillary Prescott, David P. Steensma, Mikkael A. Sekeres, Gail J. Roboz, Alan List, Hagop M Kantarjian, Rami S Komrokji
Publikováno v:
Blood. 122:388-388
Background HMA are standard of care in pts with high-risk MDS and commonly used in pts with lower risk. Pts with high-risk disease post HMA failure have a poor prognosis with a median survival of 4-6 months. The prognosis of pts with low and intermed